当前位置：
X-MOL 学术
›
Adv. Drug Deliver. Rev.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Advances in local drug delivery technologies for improved rheumatoid arthritis therapy
Advanced Drug Delivery Reviews ( IF 15.2 ) Pub Date : 2024-04-24 , DOI: 10.1016/j.addr.2024.115325 Xiaoran An 1 , Jiapei Yang 1 , Xiaolin Cui 1 , Jiaxuan Zhao 1 , Chenwei Jiang 1 , Minglu Tang 1 , Yabing Dong 2 , Longfei Lin 3 , Hui Li 4 , Feihu Wang 1
Advanced Drug Delivery Reviews ( IF 15.2 ) Pub Date : 2024-04-24 , DOI: 10.1016/j.addr.2024.115325 Xiaoran An 1 , Jiapei Yang 1 , Xiaolin Cui 1 , Jiaxuan Zhao 1 , Chenwei Jiang 1 , Minglu Tang 1 , Yabing Dong 2 , Longfei Lin 3 , Hui Li 4 , Feihu Wang 1
Affiliation
|
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterized by an inflammatory microenvironment and cartilage erosion within the joint cavity. Currently, antirheumatic agents yield significant outcomes in RA treatment. However, their systemic administration is limited by inadequate drug retention in lesion areas and non-specific tissue distribution, reducing efficacy and increasing risks such as infection due to systemic immunosuppression. Development in local drug delivery technologies, such as nanostructure-based and scaffold-assisted delivery platforms, facilitate enhanced drug accumulation at the target site, controlled drug release, extended duration of the drug action, reduced both dosage and administration frequency, and ultimately improve therapeutic outcomes with minimized damage to healthy tissues. In this review, we introduced pathogenesis and clinically used therapeutic agents for RA, comprehensively summarized locally administered nanostructure-based and scaffold-assisted drug delivery systems, aiming at improving the therapeutic efficiency of RA by alleviating the inflammatory response, preventing bone erosion and promoting cartilage regeneration. In addition, the challenges and future prospects of local delivery for clinical translation in RA are discussed.
中文翻译：
改善类风湿性关节炎治疗的局部给药技术的进展
类风湿性关节炎（RA）是一种慢性炎症性自身免疫性疾病，其特征是关节腔内的炎症微环境和软骨侵蚀。目前，抗风湿药物在 RA 治疗中取得了显着的效果。然而，它们的全身给药受到病灶区域药物保留不足和非特异性组织分布的限制，从而降低了疗效并增加了因全身免疫抑制而引起的感染等风险。局部药物递送技术的发展，例如基于纳米结构和支架辅助的递送平台，有利于增强药物在靶点的积累，控制药物释放，延长药物作用持续时间，减少剂量和给药频率，最终改善治疗效果对健康组织的损害最小化的结果。在这篇综述中，我们介绍了RA的发病机制和临床使用的治疗药物，全面总结了基于纳米结构和支架辅助的局部给药系统，旨在通过减轻炎症反应、防止骨侵蚀和促进软骨生长来提高RA的治疗效率再生。此外，还讨论了 RA 临床转化局部递送的挑战和未来前景。
更新日期：2024-04-24
中文翻译：
改善类风湿性关节炎治疗的局部给药技术的进展
类风湿性关节炎（RA）是一种慢性炎症性自身免疫性疾病，其特征是关节腔内的炎症微环境和软骨侵蚀。目前，抗风湿药物在 RA 治疗中取得了显着的效果。然而，它们的全身给药受到病灶区域药物保留不足和非特异性组织分布的限制，从而降低了疗效并增加了因全身免疫抑制而引起的感染等风险。局部药物递送技术的发展，例如基于纳米结构和支架辅助的递送平台，有利于增强药物在靶点的积累，控制药物释放，延长药物作用持续时间，减少剂量和给药频率，最终改善治疗效果对健康组织的损害最小化的结果。在这篇综述中，我们介绍了RA的发病机制和临床使用的治疗药物，全面总结了基于纳米结构和支架辅助的局部给药系统，旨在通过减轻炎症反应、防止骨侵蚀和促进软骨生长来提高RA的治疗效率再生。此外，还讨论了 RA 临床转化局部递送的挑战和未来前景。
京公网安备 11010802027423号